HR 1046 116th Congress House Health Competition and antitrust Drug safety, medical device, and laboratory regulation Health care costs and insurance Inflation and prices Licensing and registrations Manufacturing Medicare Prescription drugs Product safety and quality Public contracts and procurement

Medicare Negotiation and Competitive Licensing Act of 2019

Introduced: February 7, 2019 Introduced by: Doggett, Lloyd Democratic · Texas See on congress.gov

Everywhere this bill has been 5 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Sep 25, 2019

Subcommittee Hearings Held.

Feb 8, 2019

Referred to the Subcommittee on Health.

Feb 7, 2019

Referred to the Subcommittee on Health.

Feb 7, 2019

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Feb 7, 2019

Introduced in House

Plain-English summary Congressional Research Service

Medicare Negotiation and Competitive Licensing Act of 2019

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)

The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.

Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

What's happening now September 25, 2019

Subcommittee Hearings Held.

Committees of jurisdiction 4

Energy and Commerce Committee
House of Representatives
Health Subcommittee
House of Representatives · subcommittee of Ways and Means Committee
Health Subcommittee
House of Representatives · subcommittee of Energy and Commerce Committee
Ways and Means Committee
House of Representatives